Literature DB >> 20130568

Proof of concept: a PhRMA position paper with recommendations for best practice.

M E Cartwright1, S Cohen, J C Fleishaker, S Madani, J F McLeod, B Musser, S A Williams.   

Abstract

Proof of concept (POC) may be defined as the earliest point in the drug development process at which the weight of evidence suggests that it is "reasonably likely" that the key attributes for success are present and the key causes of failure are absent. POC is multidimensional but is focused on attributes that, if not addressed, represent a threat to the success of the project in crucial areas such as safety, efficacy, pharmaceutics, and commercial and regulatory issues. The appropriate weight of evidence is assessed through the use of mathematical models and by evaluating the consequences of advancing a candidate drug that is not safe, effective, or commercially viable, vs. failing to advance a candidate that possesses these attributes. Tools for POC include biomarkers, targeted populations, pharmacokinetic (PK)/pharmacodynamic (PD) modeling, simulation, and adaptive study designs. Challenges to the success of POCs include a shortage of skilled personnel, failure to integrate multiple disciplines and information, and the demand made by organizations for certainty.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130568     DOI: 10.1038/clpt.2009.286

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  A decade of innovation in pharmaceutical R&D: the Chorus model.

Authors:  Paul K Owens; Eyas Raddad; Jeffrey W Miller; John R Stille; Kenneth G Olovich; Neil V Smith; Rosie S Jones; Joel C Scherer
Journal:  Nat Rev Drug Discov       Date:  2014-12-15       Impact factor: 84.694

Review 2.  Conducting clinical research in community mental health settings: Opportunities and challenges.

Authors:  Oleg V Tcheremissine; Whitney E Rossman; Manuel A Castro; Dineen R Gardner
Journal:  World J Psychiatry       Date:  2014-09-22

3.  Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds.

Authors:  Emily Caton; Elizabeth Nenortas; Rahul P Bakshi; Theresa A Shapiro
Journal:  Curr Protoc Chem Biol       Date:  2016-03-16

4.  Model system to define pharmacokinetic requirements for antimalarial drug efficacy.

Authors:  Rahul P Bakshi; Elizabeth Nenortas; Abhai K Tripathi; David J Sullivan; Theresa A Shapiro
Journal:  Sci Transl Med       Date:  2013-10-02       Impact factor: 17.956

5.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16

6.  CONSORT 2010 statement: extension to randomised pilot and feasibility trials.

Authors:  Sandra M Eldridge; Claire L Chan; Michael J Campbell; Christine M Bond; Sally Hopewell; Lehana Thabane; Gillian A Lancaster
Journal:  BMJ       Date:  2016-10-24

7.  Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.

Authors:  Zhaoyang Teng; Neeraj Gupta; Zhaowei Hua; Guohui Liu; Vivek Samnotra; Karthik Venkatakrishnan; Richard Labotka
Journal:  Clin Transl Sci       Date:  2017-11-23       Impact factor: 4.689

Review 8.  BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles.

Authors:  William C N Dunlop; C Daniel Mullins; Olaf Pirk; Ron Goeree; Maarten J Postma; Ashley Enstone; Louise Heron
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

9.  CONSORT 2010 statement: extension to randomised pilot and feasibility trials.

Authors:  Sandra M Eldridge; Claire L Chan; Michael J Campbell; Christine M Bond; Sally Hopewell; Lehana Thabane; Gillian A Lancaster
Journal:  Pilot Feasibility Stud       Date:  2016-10-21

10.  The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.

Authors:  T Burt; K S Button; Hhz Thom; R J Noveck; M R Munafò
Journal:  Clin Transl Sci       Date:  2017-07-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.